Anistreplase
From Wikipedia, the free encyclopedia
| Image:Anistreplase.png | |
|
Anistreplase
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C2569H3928N746O781S40 |
| Mol. mass | 59042.3 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 90 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Anistreplase is a thrombolytic drug. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.
Also known as anisoylated plasminogen streptokinase activator complex (APSAC)
|
||||||||||||||||||||||||||

